Key Takeaways:
Sanuwave Health Inc. (NASDAQ: SNWV) reported record financial results for 2025, with annual revenue climbing 35 percent to $44.1 million and providing strong guidance for 2026.
"We’re pleased to be, once more, announcing an all-time record quarter for Sanuwave on both revenues and adjusted EBITDA," CEO Morgan Frank said, highlighting the company's performance amid challenges in the wound care sector.
For the fourth quarter, revenue was $13.4 million, up 29.7 percent from the prior year. Full-year GAAP operating income stood at $4.9 million, and adjusted EBITDA grew to $13.6 million from $7.2 million in 2024.
The company guided for full-year 2026 revenue between $51.0 million and $55.0 million. The positive results come as Sanuwave navigates a shifting market shaped by CMS reimbursement and audit changes, which management sees as a long-term benefit.
The wound care product provider saw its full-year gross margin improve to 77.1 percent from 75.2 percent in 2024. The company's swing to a net income of $11.8 million for the year, from a net loss of $33.1 million in the prior year, was also driven by a positive change in the fair value of derivative liabilities.
Management noted that while gains from new distributor interest in its UltraMIST products were strong, they were partially offset by lower consumables sales as some customers exited the market. The results suggest Sanuwave is successfully capturing new business amid industry turmoil. Investors will watch the Q1 2026 earnings call for further details on margin trends.
This article is for informational purposes only and does not constitute investment advice.
